Copertina

Ticagrelor versus Adjusted‐Dose Prasugrel in Acute Coronary Syndrome with Percutaneous Coronary Intervention

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Ming‐Lung Tsai, Yuan Lin, Dong‐Yi Chen, Ming‐Shyan Lin, Chao‐Yung Wang, I‐Chang Hsieh, Ning‐I Yang, Ming‐Jui Hung, Tien‐Hsing Chen
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Clinical Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Antiplatelet Resumption Timing in Post‐Percutaneous Coronary Intervention Gastrointestinal Bleeding
di: Darrick K. Li, et al.
Pubblicazione: (2026)

CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program
di: Catherine Chanfreau‐Coffinier, et al.
Pubblicazione: (2025)

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT ‐ ACS Emulation Using National Health Insurance Claims Data
di: Li‐Wen Huang, et al.
Pubblicazione: (2025)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
di: Pei‐Chien Tsai, et al.
Pubblicazione: (2026)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
di: Xiao‐Dong Zhou, et al.
Pubblicazione: (2025)

Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline–A Step Toward Functional Cure or a Marginal Margin?
di: Yao‐Chun Hsu, et al.
Pubblicazione: (2026)

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention
di: Danwei Shao, et al.
Pubblicazione: (2026)

Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes
di: Na Tian, et al.
Pubblicazione: (2025)

Editorial on ‘Early HBcrAg and Anti‐ HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation: A Pooled Analysis of Two Clinical Trials’
di: Ming Chao Tsai, et al.
Pubblicazione: (2025)

Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues
di: Tyng‐Yuan Jang, et al.
Pubblicazione: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
di: Jee‐Fu Huang, et al.
Pubblicazione: (2026)

Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article
di: Guiping Wang, et al.
Pubblicazione: (2024)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
di: Pei‐Chien Tsai, et al.
Pubblicazione: (2025)

Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention
di: Mo‐Yao Tan, et al.
Pubblicazione: (2024)

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes
di: Shih‐Hsuan Lin, et al.
Pubblicazione: (2026)

The Effect of Low‐Dose Colchicine on the Phenotype and Function of Neutrophils and Monocytes in Patients with Chronic Coronary Artery Disease: A Double‐Blind Randomized Placebo‐Controlled Cross‐Over Study
di: Helin Tercan, et al.
Pubblicazione: (2024)

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma
di: Jia‐Ling Wu, et al.
Pubblicazione: (2025)

The Impact of QT‐Prolonging Medications and Drug–Drug Interactions on QTc Interval Prolongation in Hospitalized Patients: A Case‐Crossover Study
di: Hsiu‐Ting Chien, et al.
Pubblicazione: (2024)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
di: Yi‐Ping Hung, et al.
Pubblicazione: (2024)

Modeling and Simulation to Inform Apixaban Dosing in Pediatrics With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated With Asparaginase
di: Praneeth Jarugula, et al.
Pubblicazione: (2025)

Letermovir Prophylaxis for CMV DNAemia /Disease after HLA ‐Mismatched HSCT : A Retrospective Real‐World Analysis with Overlap Propensity Score Weighting
di: Yi‐Che Huang, et al.
Pubblicazione: (2025)

Transdermal Nicotine Patch Increases the Number and Function of Endothelial Progenitor Cells in Young Healthy Nonsmokers without Adverse Hemodynamic Effects
di: Yen‐Yu Liu, et al.
Pubblicazione: (2024)

Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage Form
di: Vivek Purohit, et al.
Pubblicazione: (2024)

Research Communication: Changing Aetiology of Chronic Liver Diseases in East Asia Pacific and HCC Surveillance in Non‐Cirrhotic Patients
di: Ming Liu, et al.
Pubblicazione: (2025)

Comparative Safety of Tenecteplase and Alteplase in Direct Oral Anticoagulant‐Pretreated Patients With Acute Ischemic Stroke
di: Hsu‐Wei Lin, et al.
Pubblicazione: (2025)

Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk
di: Julia Karady, et al.
Pubblicazione: (2024)

Optimal Drug, Optimal Dose, or Both in the Pharmacological Treatment of Neonatal Opioid Withdrawal Syndrome?
di: Walter K. Kraft
Pubblicazione: (2025)

MELD 3.0 Improves Risk Stratification and Mortality Prediction in Hepatorenal Syndrome‐Acute Kidney Injury: A Multicentre Study
di: Jing Ma, et al.
Pubblicazione: (2025)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity?
di: Xiao‐Dong Zhou, et al.
Pubblicazione: (2025)

Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T‐Cell Engagers Development in Oncology
di: Mohamed Elmeliegy, et al.
Pubblicazione: (2024)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
di: Rui Zhang, et al.
Pubblicazione: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients
di: Ming‐Lun Yeh, et al.
Pubblicazione: (2024)

Letter: Social work and clinical synergy—Optimising health interventions for elderly DGBI populations
di: Rui Zhang, et al.
Pubblicazione: (2024)

Letter: ‘Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation’
di: You‐Jian Xu, et al.
Pubblicazione: (2024)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
di: C. C. Mark Cheah, et al.
Pubblicazione: (2025)

Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
di: Yu‐Ping Chang, et al.
Pubblicazione: (2025)

Pharmacokinetic Modeling and Model‐Based Hypothesis Generation for Dose Optimization of Clonidine in Neonates With Neonatal Opioid Withdrawal Syndrome
di: Fei Tang, et al.
Pubblicazione: (2024)

Real‐World Edoxaban Concentrations in Older Patients Receiving Reduced‐Dose Regimens
di: Sung‐Chun Tang, et al.
Pubblicazione: (2025)

Clinical Pharmacology Characterization of Bispecific T‐Cell Engagers: A Summary Based on FDA Approvals
di: Ting Wang, et al.
Pubblicazione: (2025)

Balancing Reassurance and Vigilance: Real‐World Evidence in Post‐Marketing Drug Safety
di: Yow‐Ming C. Wang, et al.
Pubblicazione: (2026)